| June 30, 2005 |
| November 19, 2008 |
| June 2005 |
| May 2007 (final data collection date for primary outcome measure) |
| Percentage of Participants Who Experienced an Adverse Event [ Time Frame: Months 1, 2, 3, 4, 6, 9, 12, 15, 18 ] [ Designated as safety issue: Yes ] |
| To evaluate the safety of 1, 2, or 3 16-week cycles of imiquimod for the treatment of actinic keratosis lesions totaling greater than 25 square centimeters |
| Complete list of historical versions of study NCT00116649 on ClinicalTrials.gov Archive Site |
| Percent Reduction From Baseline to the Final Follow-up in Total Actinic Keratosis Lesion Count [ Time Frame: At Month 18 ] [ Designated as safety issue: No ] |
| To evaluate the efficacy of treatment with imiquimod in this population of subjects with actinic keratosis |
| |
| Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis |
| Open-Label Safety and Pharmacokinetic Study of AldaraTM (Imiquimod) Cream, 5% for One, Two, or Three Treatment Cycles to Surface Areas Greater Than 25 cm2 With Actinic Keratosis |
Actinic keratosis (AK) is a skin condition that shows up on skin routinely exposed to the sun, such as the face, scalp, shoulders, chest, back, arms, and hands. The purpose of this study is to evaluate the safety of one, two, or three cycles of imiquimod for the treatment of AK. The AK lesions treated can be in adjacent and nonadjacent areas of the head, torso, and extremities. The total surface area for the AK lesions must be greater than 25 cm2. The secondary objective is to evaluate the effectiveness of treatment with imiquimod in people with large surface areas of AK. |
This was a Phase 4, open-label, single-arm, multicenter study in male and female subjects aged 18 years or older with clinically diagnosed AK lesions, conducted at 31 investigational sites in the United States.
This study assessed the safety of imiquimod as a treatment for AK applied in doses ranging from one packet 12.5 mg) to 6 packets (75 mg) to either single or multiple body regions for up to 3 cycles, depending upon treatment success and AK lesion recurrence. Eligible subjects applied imiquimod 5% cream prior to normal sleeping hours 2 days per week to at least 4 clinically typical, visible, discrete, nonhypertrophic AK lesions in contiguous or noncontiguous treatment areas totaling greater than 25 cm2 at baseline. Multiple treatment areas could be exposed (i.e., head, torso and/or extremities), with the number of packets determined by the investigator but not to exceed one packet for each 25 cm2 treatment area, up to a maximum of 6 packets per dose. In each treatment cycle, dosing was to continue for 16 weeks (approximately 4 months), as instructed by the investigator, followed by a 2-month, treatment-free follow-up period. |
| Phase IV |
| Interventional |
| Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
| Keratosis |
| Drug: imiquimod cream |
| Experimental: Aldara® (imiquimod) cream, 5% supplied in 250 mg single-use packets. |
| |
| |
| Completed |
| 551 |
| May 2007 |
| May 2007 (final data collection date for primary outcome measure) |
Inclusion Criteria:
- Are at least 18 years of age.
- Have greater than 25 cm2 total treatment area(s) containing at least 4 actinic keratosis lesions.
Exclusion Criteria:
- Have any skin condition in the treatment area that may be made worse by treatment with imiquimod (e.g., rosacea, psoriasis, atopic dermatitis, eczema).
- Have received specific treatments/medications in the treatment area(s) within the designated time period prior to study treatment initiation.
|
| Both |
| 18 Years and older |
| No |
| Contact information is only displayed when the study is recruiting subjects |
| United States |
| |
| NCT00116649 |
| Sharon Levy, MD VP Product Development, Graceway Pharmaceuticals |
| 1520-IMIQ |
| Graceway Pharmaceuticals, LLC |
|
| Study Director: |
Sharon Levy, MD |
Graceway Pharmaceuticals, LLC |
|
|
| Graceway Pharmaceuticals, LLC |
| November 2008 |
